bit.bio

bit.bio, headquartered in the United Kingdom and founded in 2016, is an innovative player in the Biotechnology and Health Care sectors, distinguished by their slogan, "The Cell Coding Company." Their mission is to code cells for novel cures using a proprietary cell programming technology called opti-ox.

This award-winning company has developed a platform that allows for the rapid and consistent programming of human induced pluripotent stem cells (iPSCs) into desired cell types, claiming a speed approximately tenfold faster than conventional methods. This capability not only holds the promise of accelerating drug discovery but also offers alternatives to traditional research workflows through their io Cells products.

The recent $50.00M Series C investment led by M&G indicates strong investor confidence in bit.bio's potential to revolutionize cell-based therapies. With a robust team of experts, bit.bio is strategically positioned to transform medical research and therapeutic development.